Loading
Life sciences · Journal article
Al-rafidain Journal of Medical Sciences · October 14, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Chemoresistance remains one of the greatest challenges in modern oncology and is responsible for most cancer-related deaths. Growing evidence has identified non-coding RNAs (ncRNAs) as key regulators of resistance to anticancer therapy. These molecules influence a wide range of classical resistance mechanisms, including drug efflux, apoptosis evasion, epithelial–mesenchymal transition, enhanced DNA repair, altered drug metabolism, and autophagy. The growing understanding of ncRNA biology has created new opportunities for clinical translation. Non-coding RNAs show considerable promise as predictive biomarkers of treatment response and as therapeutic targets, several of which have already entered early-phase clinical evaluation. Nevertheless, significant challenges remain, including efficient and selective delivery, off-target effects, tumor heterogeneity, and redundancy in ncRNA regulatory networks.